Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Esanex Inc.
• Collaborators: Pfizer; Serenex, Inc.

Criteria

Inclusion Criteria:

• >18 years old

• histologically confirmed solid tumor malignancy

• refractory to available therapy or for which no therapy is available

• adequate organ function

Exclusion Criteria:

• CNS malignancy

• significant GI disease

• at risk for prolonged QT interval